<DOC>
	<DOC>NCT00051129</DOC>
	<brief_summary>The purpose of this study was to evaluate anecortave acetate compared to placebo for maintenance of visual acuity after 24 months of treatment in patients with subfovial choroidal neovascularization (CNV) due to exudative age-related macular degeneration (AMD).</brief_summary>
	<brief_title>Anecortave Acetate in Subfoveal Choroidal Neovascularization (CNV) Due to Wet Age-Related Macular Degeneration (AMD)</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization, Pathologic</mesh_term>
	<mesh_term>Anecortave</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>Diagnosis of exudative AMD and a primary or recurrent subfoveal CNV lesion in the study eye. Other protocoldefined inclusion criteria may apply. Under 50 years. Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>AMD</keyword>
	<keyword>anecortave acetate</keyword>
	<keyword>wet AMD</keyword>
	<keyword>age-related macular degeneration</keyword>
	<keyword>Macular Degeneration</keyword>
	<keyword>Maculopathy, Age-Related</keyword>
	<keyword>Age-Related Maculopathies</keyword>
	<keyword>Age-Related Maculopathy</keyword>
	<keyword>Maculopathies, Age-Related</keyword>
</DOC>